A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Ward
S
S
School of Health and Related Research, University of Sheffield, UK.
Morris
E
E
Bansback
N
N
Calvert
N
N
Crellin
A
A
Forman
D
D
Larvin
M
M
Radstone
D
D
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine